| Scrip Code | 523642 |
|---|---|
| NSE Symbol | PIIND |
| MSEI Symbol | NOTLISTED |
| ISIN | INE603J01030 |
| Name of company | PI INDUSTRIES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 11-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 03-08-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 11-08-2026 14:00:00 |
| End date and time of board meeting | 11-08-2026 18:30:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 1,70,230.00 | 1,70,230.00 | |
| Other income | 6,410.00 | 6,410.00 | |
| Total income | 1,76,640.00 | 1,76,640.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 68,190.00 | 68,190.00 |
| (b) | Purchases of stock-in-trade | 4,230.00 | 4,230.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 1,230.00 | 1,230.00 |
| (d) | Employee benefit expense | 26,080.00 | 26,080.00 |
| (e) | Finance costs | 790.00 | 790.00 |
| (f) | Depreciation, depletion and amortisation expense | 10,370.00 | 10,370.00 |
| (f) | Other Expenses | ||
| 1 | Net impairment losses on financial assets | 520.00 | 520.00 |
| 2 | Power, Fuel & Water | 7,990.00 | 7,990.00 |
| 3 | Environment & Pollution Control Expenses | 2,660.00 | 2,660.00 |
| 4 | Freight & Cartage | 1,460.00 | 1,460.00 |
| 5 | Advertisement & Sales Promotion | 2,360.00 | 2,360.00 |
| 6 | Travelling and Conveyance | 3,130.00 | 3,130.00 |
| 7 | Legal & professional fees | 2,870.00 | 2,870.00 |
| 8 | Repairs & Maintenance | 3,560.00 | 3,560.00 |
| 9 | Laboratory & Testing Charges | 1,570.00 | 1,570.00 |
| 10 | Other expenses | 7,640.00 | 7,640.00 |
| Total other expenses | 33,760.00 | 33,760.00 | |
| Total expenses | 1,44,650.00 | 1,44,650.00 | |
| 3 | Total profit before exceptional items and tax | 31,990.00 | 31,990.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 31,990.00 | 31,990.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 7,300.00 | 7,300.00 |
| 8 | Deferred tax | 460.00 | 460.00 |
| 9 | Total tax expenses | 7,760.00 | 7,760.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 24,230.00 | 24,230.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 190.00 | 190.00 |
| 16 | Total profit (loss) for period | 24,420.00 | 24,420.00 |
| 17 | Other comprehensive income net of taxes | 3,200.00 | 3,200.00 |
| 18 | Total Comprehensive Income for the period | 27,620.00 | 27,620.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 27,620.00 | 27,620.00 | |
| Total profit or loss, attributable to non-controlling interests | 0.00 | 0.00 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,520.00 | 1,520.00 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 16.1 | 16.1 | |
| Diluted earnings (loss) per share from continuing operations | 16.1 | 16.1 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 16.1 | 16.1 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 16.1 | 16.1 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1 The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on August 11, 2026. 2 The Consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3 The Consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) PI AgSciencies, S. de R.L. de C.V. (Formerly known as Plant Health Care de Mexico S. de R.L. de C.V.) (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care Espa�a) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ;Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited ; Associate - Solinnos Agro Sciences Private Limited. 4 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures for the nine month period ended December 31, 2025. 5 a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement resulted in a write-back of the contingent consideration of Rs. 1,260 Mn, which was presented under Exceptional Items during the year ended March 31, 2026. b) Pursuant to the notification of the New Labour Codes as issued in November 2025, the Group reassessed its employee benefit obligations in accordance with the revised definition of wages and accordingly, an incremental liability of Rs. 229 Mn had been disclosed as an Exceptional Item during the year ended March 31, 2026. 6 Segment information as per Ind AS 108 Operating Segments is as per Annexure I. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Agro Chemicals | 1,64,880.00 | 1,64,880.00 | ||||
| 2 | Pharma | 5,420.00 | 5,420.00 | ||||
| 3 | Inter Segment adjustment | 0.00 | 0.00 | ||||
| Total Segment Revenue | 1,70,300.00 | 1,70,300.00 | |||||
| Less: Inter segment revenue | 70.00 | 70.00 | |||||
| Revenue from operations | 1,70,230.00 | 1,70,230.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Agro Chemicals | 38,350.00 | 38,350.00 | ||||
| 2 | Pharma | (8,160.00) | (8,160.00) | ||||
| 3 | Inter Segment adjustment | 1,990.00 | 1,990.00 | ||||
| Total Profit before tax | 32,180.00 | 32,180.00 | |||||
| i. Finance cost | 0.00 | 0.00 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | 0.00 | 0.00 | |||||
| Profit before tax | 32,180.00 | 32,180.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Agro Chemicals | 12,45,490.00 | 12,45,490.00 | ||||
| 2 | Pharma | 1,45,610.00 | 1,45,610.00 | ||||
| 3 | Inter Segment adjustment | 0.00 | 0.00 | ||||
| Total Segment Asset | 13,91,100.00 | 13,91,100.00 | |||||
| Un-allocable Assets | 0.00 | 0.00 | |||||
| Net Segment Asset | 13,91,100.00 | 13,91,100.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Agro Chemicals | 2,06,960.00 | 2,06,960.00 | ||||
| 2 | Pharma | 37,310.00 | 37,310.00 | ||||
| 3 | Inter Segment adjustment | 0.00 | 0.00 | ||||
| Total Segment Liabilities | 2,44,270.00 | 2,44,270.00 | |||||
| Un-allocable Liabilities | 0.00 | 0.00 | |||||
| Net Segment Liabilities | 2,44,270.00 | 2,44,270.00 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | Note: The business of the group is divided into two segments as below: a) Agro chemicals - Agro chemicals includes Agchem export (CSM), Domestic Agri Brands and Biologicals. b) Pharma - Pharma comprises contract research and development, contract development and manufacturing of active, key starting materials and intermediates used in pharmaceutical industry. |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurements gain/(loss) on defined benefits plans | 90.00 | 90.00 |
| Total Amount of items that will not be reclassified to profit and loss | 90.00 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 50.00 | 50.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Effective portion of gain/(loss) on cash flow hedges | 5,710.00 | 5,710.00 |
| 2 | Exchange difference on translation of foreign operations | (550.00) | (550.00) |
| Total Amount of items that will be reclassified to profit and loss | 5,160.00 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 2,000.00 | 2,000.00 |
| 5 | Total Other comprehensive income | 3,200.00 | 3,200.00 |